Abatacept for SLE Arthritis (IM101-330)

Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE)

This research trial is for patients who have been diagnosed with systemic lupus erythematosus (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the SLE.

The purpose of this clinical research study is to evaluate the safety and effectiveness of treatment with abatacept (Abatacept) 125mg injected subcutaneously (under the skin) weekly for 16 weeks versus placebo injections(a substance with no active ingredients and therefore may have no treatment benefit) in subjects with SLE and inflammatory polyarthritis. The effectiveness will be assessed primarily by the number of swollen, tender joints (called a joint count) at each of study visits.

Study Medication Abatacept is approved in the U.S. for treating rheumatoid arthritis by prescription and has not been approved by the U.S. Food and Drug Administration for treating SLE yet.

In this study, subjects will receive treatment with either abatacept or placebo once a week for 16 weeks (a total of 16 injections).

Study Overview

• Status: Terminated
• Conditions: Systemic Lupus Erythematosus Arthritis
• Intervention / Treatment: Drug: Placebo; Biological: abatacept also known as Orencia also known as CTLA4-Ig

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90095
      • UCLA David Geffen School of Medicine, Division of Rheumatology
    • San Diego, California, United States, 92093
      • University of California, San Diego

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Meet at least 4 of the 11 American College of Rheumatology (ACR) 1997 criteria for classification of SLE (see Appendix 1).OR meet the recent classification recommended by SLICC (Appendix 2) 6
2. ≥3 swollen and tender joints on 2 examinations at least 2 weeks apart and no more than 8 weeks apart.
3. SLEDAI2K score ≥4 indicating active disease.
4. Documented positive ANA (≥1:80) and/or anti-dsDNA during course of SLE.
5. Men and women, at least 18 years of age. Women of childbearing potential must use adequate method(s) of contraception to avoid pregnancy throughout the study and for up to 2 months after last study drug dose. They must have a negative serum or urine pregnancy test prior to the start of study medication.
6. Background therapies allowed: antimalarials (dose constant for ≥ one month before study entry and during 16 weeks of trial), methotrexate (same criteria as for antimalarials), azathioprine (same criteria), mycophenolate (same criteria), leflunomide (same criteria).

During the screening period and for up to 6 weeks after randomization, a daily prednisone (or equivalent) regimen of up to 20 mg daily may be initiated to treat the moderate to severe disease activity present at screening. The initial steroid regimen is not required if investigators or patients believe that the risks would outweigh the potential benefits. Patients who do not take any glucocorticoids during the study will be included in the treatment groups and analysis.

*Steroids should be tapered to a target dose of no more than 10 mg/day of prednisone (or equivalent) by the end of Week 8 (Day 56). The steroid regimen should be tapered as quickly as safely possible. Prednisone dose requirements higher than 10 mg daily at the 8 week visit will cause the patient to be ruled a non-responder for the abatacept treatment arm.

Exclusion Criteria:

1. Subjects with active infection requiring oral or IV antibiotics within one month of first dose of study medication.
2. Subjects with BILAG A in any system outside the musculoskeletal system.
3. Subjects with positive quantiferon Gold test in the absence of treatment for tuberculosis.
4. Subjects with positive tests for active infection with hepatitis B or C during the past 6 months. Any confirmed positive test for HIV at any time prior to entry into this study.
5. Subjects with active glomerulonephritis (>3 g protein/24h and/or active urine sediment).
6. Subjects with active CNS disease.
7. Subjects with any other serious disease that would require immunosuppressive or parenteral anti-microbial therapy outside the study protocol.
8. Inability to self-administer subcutaneous injections, to comply with instructions, or to keep appointments for study visits.
9. Treatment with rituximab within the past 6 months (B cells must be detectable in peripheral blood at onset of treatment with study biologic), belimumab within the past 5 months, cyclophosphamide within the past 3 months.
10. Treatment with any other immunomodulatory biologic or cyclophosphamide during treatment with abatacept is not allowed.
11. Patients requiring >20 mg of prednisone daily.
12. Women who are pregnant or breast feeding.
13. Women of child bearing potential unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 2 months after last study drug.
14. Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection).
15. Any laboratory test results that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Abatacept also known as Orencia also known as CTLA4Ig; 32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.	Biological: abatacept also known as Orencia also known as CTLA4-Ig; 125mg injected subcutaneously weekly for 16 weeks; Other Names: Orencia
Placebo Comparator: Placebo; 32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks	Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With at Least a 20% Improvement From Baseline in Tender and Swollen 28 Joint Count	Assessed by physical exam. Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit.	Baseline, 8 Weeks, 16 Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in SLEDAI 2K	Systemic Lupus Erythematosus Disease Activity Index (Modified in the year 2000) - The SLEDAI-2K is a modified version of a composite score based on the presence or absence of clinical signs, clinical symptoms, and immunologic laboratory results taken within 10 days of the evaluations. Each of the descriptors has a weighted score and the total score of SLEDAI-2K is the sum of all 24 descriptor scores. The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity. Decrease of 3 points in SLEDAI 2K is considered to be a clinically significant improvement.	Baseline, 16 weeks
Change in the PGA Score	Physician's Global Assessment (PGA) is a physician rating of patient's disease activity, with a range 0-3. A change of 0.8 points on a 3 point scale or less is considered as stable. Lower score means better outcome	Baseline, 16 weeks
Clinical Disease Activity Index (CDAI) Index Score	CDAI is a simplified index for assessing disease activity comprising swollen joint counts (SJC), tender/painful joint counts (TJC), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA). CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment), PtGA and PGA (assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0-76. CDAI less than equal to (<=) 2.8 indicates disease remission, greater than (>) 2.8 to 10 = low disease activity, greater than (>) 10 to 22 = moderate disease activity, and >22 = high disease activity.	16 weeks
Synovitis, Tenosynovitis and Erosions Scores (GSUS and PDUS)	Using ultrasound analysis, (Gray scale ultrasound) represents synovitis/tenosynovitis and identifies erosions. PDUS (power Doppler ultrasound) measures intensity of soft tissue inflammation by blood flow. 30 joints were evaluated using a 0 to 3 point scale for each joint and the sum of these represents PDUS. The Power Doppler Synovitis Score (PDUS) ranges from 0 to 90. Scores of 0 indicate the least amount of inflammation. A higher value of the total score for PDUS represents more severe disease level. 30 joints were evaluated using a 0 to 3 point scale for each joint and the sum of these represents GSUS. The grey scale synovial hypertrophy score (GSUS) ranges from 0 to 90. Scores of 0 indicate the least amount of inflammation of the joint. A higher value of the total score for GSUS represents more severe disease level.	Baseline, 16 weeks
Number of AEs and SAEs	Total number of AEs and total number of SAEs as well as those AEs/SAEs which may be related to the study drug	16 weeks
Number of Tender and Swollen Joints	Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit	baseline, 4, 8, 12 and 16 weeks
Change in the Total Sum of Tender and Swollen Joints	Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit	Baseline, 16 weeks
Number of Patients Who Tapered Prednisone to <10mg/Day	This analysis is for the subset of patients who start the study taking 10 to 20mg of prednisone per day.	16 weeks
Mean Prednisone Dose (mg/Day)	prednisone dose (mg/day) is recorded at baseline, 8 and 16 weeks for each subject being assessed at that study visit. Then a mean for all the subjects in each group at each time point was calculated.	Baseline, 8 and 16 weeks

Collaborators and Investigators

• Sponsor: University of California, Los Angeles
• Collaborators: Bristol-Myers Squibb
• Investigators: Principal Investigator: Bevra Hahn, M.D., University of California, Los Angeles

Study record dates

Study Major Dates

• Study Start: October 1, 2015
• Primary Completion (Actual): September 1, 2019
• Study Completion (Actual): September 1, 2019

Study Registration Dates

• First Submitted: April 24, 2015
• First Submitted That Met QC Criteria: April 28, 2015
• First Posted (Estimate): April 29, 2015

Study Record Updates

• Last Update Posted (Actual): May 13, 2021
• Last Update Submitted That Met QC Criteria: May 11, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Keywords: Arthritis; Systemic Lupus Erythematosus (SLE); Abatacept (Orencia)
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Connective Tissue Diseases; Arthritis; Lupus Erythematosus, Systemic; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Immune Checkpoint Inhibitors; Abatacept
• Other Study ID Numbers: IM101-330 SLE Arthritis